The short version of reference standard fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-15 and is reviewed periodically as new material appears.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
=== Anisotropy of the interface kinetics === Even if the temperature gradient within the slurry is perfectly vertical, it is common to see tilting or curvature of the lamellae as they grow through the suspension. To explain this, it is possible to define two distinct growth directions for each ice crystal. There is the direction determined by the temperature gradient, and the one defined by the preferred growth direction crystallographically speaking. These angles are often at odds with one another, and their balance will describe the tilt of the crystal. The non-overlapping growth directions also help to explain why dendritic textures are often seen in freeze-casts. This texturing is usually found only on the side of each lamella; the direction of the imposed temperature gradient. The ceramic structure left behind shows the negative image of these dendrites. In 2013, Deville et al. made the observation that the periodicity of these dendrites (tip-to-tip distance) actually seems to be related to the primary crystal thickness.
=== Vitamin B9 (Folate) === There are many naturally occurring vitamers of vitamin B9, i.e., folate, found in minimally processed foods. Sometimes referred to as "food folates", these vitamers are characterized as pteroylpolyglutamates and contain between one and six additional glutamate molecules compared to folic acid. Folic acid, chemically described as pteroylmonoglutamic acid, is another vitamer of vitamin B9. Though rarely found in minimally processed foods, it is the primary form of vitamin B9 added to fortified foods and many dietary supplements. Folic acid and food folates are absorbed and metabolized by different pathways. After digestion, food folates are converted in the small intestine to 5-methyltetrahydrofolic acid, a biologically active vitamer of vitamin B9. Folic acid is absorbed and transported in the bloodstream to the liver, where it is converted to tetrahydrofolate, a second biologically active vitamer, by dihydrofolate reductase. The liver has a limited capacity to metabolize folic acid into tetrahydrofolate. Any folic acid that is not converted to tetrahydrofolate in the liver remains in the blood until it is either metabolized in the liver or excreted by the kidney. Folic acid that remains in the blood stream is considered unmetabolized folic acid. Since the introduction of mandatory folic acid fortification in the US, most people have a variable amount of unmetabolized folic acid circulating in their blood.
=== Anna Gearing === Anna Gearing (Elena Saurel) is the head of FutureDawn Partners, a socially conscious investment fund. Despite her ethical business philosophy, Anna is shown to have expensive personal tastes, and micromanages employees at her fund. She has two daughters, with her longtime portfolio manager Petra Koenig as their godmother. Anna first appears as a client of Pierpoint, with Yasmin Kara-Hanani hedging her FX exposure. Harper meets Anna at a Pierpoint-organized duck shoot in Wales tied to healthcare startup Rican, where Anna bluntly assesses Rican as fundamentally underperforming and incapable of delivering on its social mission. Harper uses this insight to convince Jesse Bloom to buy out Anna’s stake—after already selling him $3.3 billion in shares—securing his controlling interest and long-term profit. After Harper is fired from Pierpoint, she joins FutureDawn as Anna’s executive assistant, but quickly aligns herself with Petra, who grows disillusioned with Anna’s leadership. Tensions peak when Harper helps Petra hedge Lumi IPO exposure by buying credit default swaps on fossil-fuel assets, directly contradicting FutureDawn’s ethical stance. Harper and Petra ultimately break away to form their own hedge fund, publicly announcing the move at a Swiss climate conference attended by Anna.
=== DNA repair === Two classical DNA repair pathways, nucleotide excision repair and base excision repair, are present in hydra, and these repair pathways facilitate unhindered reproduction. The identification of these pathways in hydra is based, in part, on the presence in the hydra genome of genes homologous to genes in other genetically well studied species that have been demonstrated to play key roles in these DNA repair pathways.
Sources: en.wikipedia.org
In the West, the glass is normally a borosilicate glass (similar to Pyrex), while in the former Soviet Union it is normal to use a phosphate glass. The amount of fission products in the glass must be limited because some (palladium, the other Pt group metals, and tellurium) tend to form metallic phases which separate from the glass. Bulk vitrification uses electrodes to melt soil and wastes, which are then buried underground. In Germany, a vitrification plant is treating the waste from a small demonstration reprocessing plant which has since been closed.
Plutonium-241 is a beta emitter with a half-life of 14.33 years, corresponding to a decay of about 5% of 241Pu nuclei over a one-year period. This decay has a Q-value of only 20.8 keV, and does not emit gamma rays. The longer spent nuclear fuel waits before reprocessing, the more 241Pu decays to americium-241, which is nonfissile (although fissionable by fast neutrons) and an alpha emitter with a half-life of 432.6 years; 241Am, which does emit gamma rays, is a major contributor to the radioactivity of nuclear waste on a scale of hundreds to thousands of years. In its fully ionized state, the beta-decay half-life of 241Pu94+ decreases to 4.2 days, and only bound-state beta decay is possible. Plutonium-241 also has a rare alpha decay branch to uranium-237, occurring in about 0.0025% of decays. Unlike its usual beta decay, this can emit gamma rays, X-rays, and associated electrons.
== Background == Sudan had multi-member Sovereignty Councils holding the role of head of state of Sudan several times during the twentieth century. Following more than half a year of sustained civil disobedience and a shift of the presidency from Omar al-Bashir to the Transitional Military Council (TMC) in April 2019 by a coup d'état, the TMC and the Forces of Freedom and Change alliance (FFC) made a July 2019 Political Agreement and completed it by the August 2019 Draft Constitutional Declaration. Articles 9.(a) and 10.(a) of the August 2019 Draft Constitutional Declaration both transfer the role of head of state to the Sovereignty Council.
=== Injection procedures === Routes of administration of injections in laboratory mice are mainly subcutaneous, intraperitoneal and intravenous. Intramuscular administration is not recommended due to small muscle mass. Intracerebral administration is also possible. Each route has a recommended injection site, approximate needle gauge and recommended maximum injected volume at a single time at one site, as given in the table below:
The city of Moscow is led by a single mayor, Sergey Sobyanin. The city is divided into 12 administrative okrugs and 125 districts. Moscow's urban planning appeared as early as the 12th century, when the city was founded. The city center grew by amalgamating with suburbs, in keeping with medieval principles of urban development, as strong fortress walls gradually spread along the circular streets of adjacent new settlements. The first circular defense walls established the trajectory for Moscow's rings, laying the groundwork for future city planning. The following fortifications served as the city's circular defense boundaries at some point in history:
Sources: en.wikipedia.org
== Function == Glutathione synthetase is important for a variety of biological functions in multiple organisms. In Arabidopsis thaliana, low levels of glutathione synthetase have resulted in increased vulnerability to stressors such as heavy metals, toxic organic chemicals, and oxidative stress. The presence of a thiol functional group allows its product GSH to serve both as an effective oxidizing and reducing agent in numerous biological scenarios. Thiols can easily accept a pair of electrons and become oxidized to disulfides, and the disulfides can be readily reduced to regenerate thiols. Additionally, the thiol side chain of cysteines serve as potent nucleophiles and react with oxidants and electrophilic species that would otherwise cause damage to the cell. Interactions with certain metals also stabilize thiolate intermediates. In humans, glutathione synthetase functions in a similar manner. Its product GSH participates in cellular pathways involved in homeostasis and cellular maintenance. For instance, glutathione peroxidases catalyze the oxidation of GSH to glutathione disulfide (GSSG) by reducing free radicals and reactive oxygen species such as hydrogen peroxide. Glutathione S-transferase uses GSH to clean up various metabolites, xenobiotics, and electrophiles to mercapturates for excretion. Because of its antioxidant role, GSS mostly produce GSH inside the cytoplasm of liver cells and imported to mitochondria where detoxification occurs. GSH is also essential for the activation of the immune system to generate robust defense mechanisms against invading pathogens.
== Prostate cancer == Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), and as a monotherapy at a dosage of 150 mg/day for the treatment of stage C or D1 locally advanced prostate cancer (LAPC). Although effective in mPC and LAPC, bicalutamide is no longer indicated for the treatment of localized prostate cancer (LPC) due to negative findings in the Early Prostate Cancer (EPC) clinical trial programme. Prior to the introduction of the newer NSAA enzalutamide in 2012, bicalutamide was considered to be the standard-of-care antiandrogen in the treatment of prostate cancer, and still remains widely used for this indication. Compared to earlier antiandrogens like the steroidal antiandrogen (SAA) cyproterone acetate (CPA) and the NSAAs flutamide and nilutamide, bicalutamide shows an improved profile of effectiveness, tolerability, and safety, and for this reason has largely replaced them in the treatment of prostate cancer. In the early 1940s, it was discovered that growth of prostate cancer in men regressed with surgical castration or high-dose estrogen therapy, which produced very low levels of circulating testosterone, and accelerated with the administration of exogenous testosterone.
Evidence for the important role antithrombin plays in regulating normal blood coagulation is demonstrated by the correlation between inherited or acquired antithrombin deficiencies and an increased risk of any affected individual developing thrombotic disease. Antithrombin deficiency generally comes to light when a patient suffers recurrent venous thrombosis and pulmonary embolism.
1. "Unichem, Optimus enter into strategic tie-up”. The Hindu Business Line.com. Published on 5 November 2018. 2. “Unichem to acquire 20% stake in Optimus group for Rs 120 cr”. Business-standard.com. Published on 5 November 2018. 3. “Unichem Labs gets USFDA nod for asthma drug”. Economictimes.com. Published on 4-July-2018. 4. “Unichem Labs' Ghaziabad unit gets EIR from USFDA” Thebusinessline.com. Published on 5 June 2018. 2018. 5. “Unichem Laboratories Gets ANDA Approval from U.S. FDA for Valsartan Tablets, USP.” Reuters.com. Published on 7 May 2018. 6. “How Torrent Pharma is integrating Unichem to boost its domestic business.” Business-standard.com. Published on 13 February 2018. 7. “Torrent Pharma completes acquisition of Unichem Laboratories Ltd.” Economictimes.com. Published on 14 December 2017. 8. “This conventional businessman is set for second innings”. Economictimes.indiatimes.com. Published on 4 November 2017. 9. “Unichem Labs gets EIR from USFDA for Goa facility” Economics times.com. Published on 30 June 2017. 10. "Unichem Lab appoints Mr. Bhagwat S. Dhingra as Chief Executive-Domestic Pharma". Moneycontrol.com. 13 August 2012. 11. "Contact Pharmaceutical Company India - Unichem Laboratories". Unichemlabs.com. Retrieved 3 October 2010. 12. "Interview of Dr P A Mody, CEO, Unichem Laboratories Ltd". Indiainfoline.com. Retrieved 3 October 2010. 13. "BSE Plus". Bseindia.com. Retrieved 3 October 2010. 14. "Pharmaceutical Business, Pharma Business Development - Unichem Laboratories". Unichemlabs.com. Retrieved 3 October 2010. 15.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.